NCT03944109View on ClinicalTrials.gov

The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

June 20, 2019

Primary Completion Date

December 22, 2020

Study Completion Date

December 22, 2020

Conditions

Hyperlipidemia

Interventions

DRUG

SHR-1209

"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"

DRUG

Placebo

"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"

Trial Locations (1)

Unknown

Sun Yat-Sen Memorial Hospital ,The Second Affiliated Hospital of Sun Yat-Sen University, Guangzhou

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT03944109 - The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia | Biotech Hunter | Biotech Hunter